

---

---

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 8-K

### CURRENT REPORT

#### PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) **October 10, 2006**



**CHEMBIO DIAGNOSTIC, INC.**  
(Exact name of registrant as specified in its charter)

**Nevada**  
(State or other jurisdiction  
of Incorporation)

**0-30379**  
(Commission File Number)

**88-0425691**  
(IRS Employer  
Identification Number)

**3661 Horseblock Road**  
**Medford, NY 11763**  
(Address of principal executive offices)  
**631-924-1135**  
(Registrant's Telephone Number)

**N/A**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

---

#### ITEM 7.01. Regulation FD Disclosures.

On October 10, 2006 the Registrant issued the press release titled "Chembio to Host Conference Call to Discuss Marketing Partner Agreements for Rapid HIV Tests" included herein as Exhibit 99.1.

#### ITEM 9.01. Financial Statements and Exhibits

(d) Exhibits.

99.1 Press Release titled "[Chembio to Host Conference Call to Discuss Marketing Partner Agreements for Rapid HIV Tests](#)" issued October 10, 2006.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date:        October 10, 2006

ChemBio Diagnostics, Inc.

By: /s/ Lawrence A. Siebert  
Lawrence A. Siebert  
Chief Executive Officer

---

---



**ChemBio to Hold Conference Call Today at 4:30 EST  
to Discuss Marketing Partner Agreements for Rapid HIV Tests**

NEW YORK--(BUSINESS WIRE)--October 10, 2006--ChemBio Diagnostics, Inc. (OTCBB:CEMI - News) will host a conference call today, Tuesday October 10<sup>th</sup> at 4:30pm EST to discuss the recently announced financing and marketing partner agreements for ChemBio's rapid HIV tests.

ChemBio invites all those interested in hearing management's discussion of the recent events to join the call by dialing (877) 407-0782. International participants may access the call by dialing 201-689-8567.

A live web cast can be accessed by clicking on the following link <http://www.vcall.com/IC/CEPage.asp?ID=109970>. A replay of this web cast can also be accessed using the same link.

**ABOUT CHEMBIO**

ChemBio Diagnostics, Inc., a developer and manufacturer of rapid diagnostic tests for infectious diseases, is on the frontlines of the global battle against the AIDS pandemic. The Company has received marketing approval from the FDA for its SURE CHECK(R) HIV 1/2 and HIV 1/2 STAT-PAK(TM) rapid tests. The Company also manufactures rapid tests for veterinary Tuberculosis and Chagas Disease, and has developed a patent-pending technology, the Dual Path Platform (DPP(TM)), for its next generation HIV and other rapid tests. For additional information please visit [www.chembio.com](http://www.chembio.com).

**FORWARD-LOOKING STATEMENTS**

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only, as the Company has not completed the preparation of its financial statements for those periods, nor has its auditor completed the audit of those results. Actual revenue may differ materially from those anticipated in this press release. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to ChemBio's ability to obtain additional financing, to obtain regulatory approvals in a timely manner, and the demand for ChemBio's products. ChemBio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in ChemBio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact ChemBio's success are more fully disclosed in ChemBio's most recent public filings with the U.S. Securities and Exchange Commission.

**Contact:**

The Investor Relations Group

Investors:

James Carbonara, 212-825-3210

or

Media:

Susan Morgenbesser, 212-825-3210

Source: ChemBio Diagnostics, Inc.

---